Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
about
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetesInterventions for latent autoimmune diabetes (LADA) in adultsInterventions for latent autoimmune diabetes (LADA) in adultsPersistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assayRecovery of endocrine function after islet and pancreas transplantationImmune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experienceType 1 diabetesImmunotherapy in autoimmune type 1 diabetesIL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetesDefining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus reportDisease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Type 1 diabetes: translating mechanistic observations into effective clinical outcomesProtocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive studyIslet β-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model.Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet dataImpact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.Residual β-Cell Function Predicts Clinical Response After Autologous Hematopoietic Stem Cell Transplantation.Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data2011 Update: antigen-specific therapy in type 1 diabetesLeptin revisited: its mechanism of action and potential for treating diabetes.A predictive model for lack of partial clinical remission in new-onset pediatric type 1 diabetes.Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes ManagementA Practical Review of C-Peptide Testing in DiabetesCurrent and future management of diabetic retinopathy: a personalized evidence-based approach.Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.Early hyperglycemia detected by continuous glucose monitoring in children at risk for type 1 diabetes.Treatment of type 1 diabetes with adipose tissue-derived stem cells expressing pancreatic duodenal homeobox 1.HLA genes, islet autoantibodies and residual C-peptide at the clinical onset of type 1 diabetes mellitus and the risk of retinopathy 15 years later.Early prediction of autoimmune (type 1) diabetes.Age at onset and the risk of proliferative retinopathy in type 1 diabetesType 1 Diabetes TrialNet--an international collaborative clinical trials networkStarting subcutaneous insulin doses in a paediatric population with newly diagnosed type 1 diabetes.Recommendations for the definition of clinical responder in insulin preservation studiesUrinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes.Characteristics and determinants of partial remission in children with type 1 diabetes using the insulin-dose-adjusted A1C definitionLeptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in miceInsulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study.Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.The effectiveness and durability of an early insulin pump therapy in children and adolescents with type 1 diabetes mellitus
P2860
Q21134119-E3C7E3C5-3B20-40E7-B72C-1B42DB52E32DQ24234365-1D95D3E7-1FCC-4364-B753-3E138ECA6A29Q24244270-B57A767E-598E-4443-BF46-EF547D3AB802Q24600478-5D538E0D-0463-456A-BCC1-2448D606D2B2Q26822596-EADA4824-B925-4F1D-90C7-A4815DB70682Q26850621-E9AEA2F6-0A42-41AC-8C76-5E3F11093988Q27000491-FD8C6B4F-4F62-4E97-B5CF-D6019DAA32BDQ27025619-8BEFDE7E-7EFE-4018-831B-75B2B9508BD8Q27303126-2A612EA0-9426-46DF-A317-F0FD48C58D75Q27687598-674DAD9D-60A1-4AD1-8670-051C1D84E473Q28081034-8490961E-6A4C-45C6-A117-7312AE2F663DQ28287737-FEB3E489-85B6-447B-B0E5-193D89EBEC4CQ28604189-69EC4AB6-667C-4EC0-A58F-A8AA74156916Q30421540-C8457A5A-2655-4A31-9228-927755A95A21Q30521476-4E47423E-3A05-44C4-94C2-A00908D8DE75Q30567434-BF176E4F-6F9E-44AF-861B-E74DCE9FF3F1Q30743822-D07A1BB0-DB3E-4095-B88A-CE17E8B657C9Q31099230-28A2CE19-DECA-4021-B1F6-4E9FE731A0F2Q31144148-9BBD7381-2968-4A27-9B78-C901A68F64FFQ33593629-BFE85089-8285-484B-9D95-64CC9399142EQ33602487-94D16590-76D8-446A-A600-D3B574B1D9B7Q33620874-AD9F5437-2C20-4F04-86C7-0DFBBB3C91DEQ33621582-44529061-D653-49E1-B24A-0C4E33C96A6EQ33732640-1829D248-4941-4697-AC4E-695D266FDEE4Q33738829-EA8C41E0-E08F-421D-9F13-DDDB3946E11BQ33744839-9C116F04-857D-4E6A-B373-D29D8A10A751Q33793829-32B8FABE-253C-48F3-858C-0652335A3542Q33820318-16C413EA-7AB1-478E-923E-016B7AE82739Q33848973-4320020D-04E3-4223-9B12-F3C0C2CA84D4Q33854613-CF7862E4-9E88-4DC5-95D1-204FB70F8ACCQ33873142-7D701DE7-B833-4A5E-B681-B9FCF8294636Q34055005-88849C8B-FA36-4F00-A9BC-51CC775BC4E1Q34066125-81E64404-C33C-4F91-B68C-CF6F0270797FQ34077400-4DC91EE8-EBDF-451B-8A35-FFA5D546552DQ34131203-B4BCE898-154C-4C25-90F3-B80007A96705Q34181376-DFE94BA4-2B1F-41ED-A2E5-E69E912493F5Q34182689-B882FC76-A976-47AF-BAFC-E9F489CFD1FBQ34207348-2B961C49-43BA-403F-B854-FC43C0B6252AQ34237680-F904D339-82A7-4076-9AA6-80647EF9ED0CQ34360873-F42CB070-9366-41BC-A094-D226E4266E6C
P2860
Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Beta-cell function and the dev ...... ntrol and complications trial.
@en
Beta-cell function and the dev ...... ntrol and complications trial.
@nl
type
label
Beta-cell function and the dev ...... ntrol and complications trial.
@en
Beta-cell function and the dev ...... ntrol and complications trial.
@nl
prefLabel
Beta-cell function and the dev ...... ntrol and complications trial.
@en
Beta-cell function and the dev ...... ntrol and complications trial.
@nl
P2093
P356
P1433
P1476
Beta-cell function and the dev ...... ntrol and complications trial.
@en
P2093
Melissa Jackson
Michael W Steffes
Shalamar Sibley
William Thomas
P304
P356
10.2337/DIACARE.26.3.832
P407
P577
2003-03-01T00:00:00Z